Pacira BioSciences, Inc. (PCRX) financial statements (2021 and earlier)

Company profile

Business Address 5 SYLVAN WAY
PARSIPPANY, NJ 07054
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments522292383311173159157
Cash and cash equivalents1007813354365738
Short-term investments422214251257137102119
Receivables53483832302622
Inventory, net of allowances, customer advances and progress billings65584941316229
Inventory65584941316229
Other undisclosed current assets121187966
Total current assets:652409478391243253214
Noncurrent Assets
Operating lease, right-of-use asset74 
Property, plant and equipment1371051091071019061
Long-term investments and receivables95652660 1324
Long-term investments95652660 1324
Intangible assets, net (including goodwill)1962046255473124
Goodwill1001006255473124
Intangible assets, net (excluding goodwill)97104   00
Deferred income tax assets106 
Other noncurrent assets  11123
Other undisclosed noncurrent assets14491414   
Total noncurrent assets:623423211237148137112
TOTAL ASSETS:1,275831689628391390326
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities82856056444444
Accounts payable10131415897
Accrued liabilities71704641373528
Employee-related liabilities      9
Taxes payable010000 
Debt150 00  120
Asset retirement obligation 1     
Deferred revenue and credits0111
Other undisclosed current liabilities2223   106(26)
Total current liabilities:253108615645152140
Noncurrent Liabilities
Long-term debt and lease obligation384306291276109  
Long-term debt, excluding current maturities313306291276109  
Operating lease, liability71 
Liabilities, other than long-term debt421716192019
Deferred revenue and credits 7814
Other liabilities42171611115
Other undisclosed noncurrent liabilities1461    (5)
Total noncurrent liabilities:4013683072931282015
Total liabilities:655476368349172171155
Stockholders' equity
Stockholders' equity attributable to parent620355321279219218171
Common stock0000000
Additional paid in capital873754710669565527481
Accumulated other comprehensive income (loss)00(0)(0)(0)(0)(0)
Accumulated deficit(254)(399)(388)(389)(346)(308)(310)
Total stockholders' equity:620355321279219218171
TOTAL LIABILITIES AND EQUITY:1,275831689628391390326

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues430421337287276249198
Revenue, net334286273248196
Cost of revenue(117)(107)(87)(88)(110)(72)(77)
Gross profit:312314250199166177120
Operating expenses(261)(411)(321)(312)(308)(240)(203)
Other undisclosed operating income (loss)(5)10787881107277
Operating income (loss):461016(25)(32)9(5)
Nonoperating expense(26)(21)(16)(18)(6)(7)(8)
Investment income, nonoperating5764110
Other nonoperating income (expense)3(5)(1)0(0)(0)(0)
Interest and debt expense(8)(24)(22)(4)(7)(0)(8)
Income (loss) from continuing operations before equity method investments, income taxes:12(34)(22)(46)(45)2(22)
Other undisclosed income from continuing operations before income taxes824224708
Income (loss) from continuing operations before income taxes:20(11)(0)(42)(38)2(14)
Income tax expense (benefit)125(0)(0)(0)(0)(0)(0)
Net income (loss) available to common stockholders, diluted:146(11)(0)(43)(38)2(14)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):146(11)(0)(43)(38)2(14)
Comprehensive income (loss):146(11)(0)(43)(38)2(14)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)10(0)00(0)
Comprehensive income (loss), net of tax, attributable to parent:146(10)(0)(43)(38)2(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: